Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2018
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
- 25 May 2016 Status changed from recruiting to active, no longer recruiting.